Open AccessA case of multiple primary lung adenocarcinoma with a CD74‐NRG1 fusion protein and HER2 mutation benefit from combined target therapy
Author(s) -
Chen Kai,
Li Wen,
Xi Xiaoming,
Zhong Jia
Publication year - 2022
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14636
Subject(s) - afatinib , medicine , epidermal growth factor receptor , neuregulin 1 , cancer research , lung cancer , erbb , adenocarcinoma , fusion protein , targeted therapy , epidermal growth factor , neuregulin , receptor , oncology , cancer , gene , gefitinib , biology , genetics , recombinant dna
Neuregulin 1 (NRG1) gene fusion is a rare oncogenic driver gene in multiple tumor types, leading to the activation of the epidermal growth factor receptor (ErbB)‐mediated pathway. Therefore, afatinib, a pan‐ErbB family inhibitor, may be a therapeutic candidate for NRG1 fusion‐driven tumors. In this case, we report a multiple primary lung adenocarcinoma patient harboring the CD74‐NRG1 fusion, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (ERBB2) mutation simultaneously. The patient received afatinib and pyrotinib combination therapy and showed a significant treatment response with a progression‐free survival of 5 months. Our case further supports the use of targeted therapy for NRG1 fusion‐positive non‐small‐cell lung cancer.